RET L629P
|
Thyroid Gland Medullary Carcinoma
|
RET L629P
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C4 – Case Studies
|
pralsetinib Sensitive: C4 – Case Studies
|
RET L629P
|
Head and Neck Cancer
|
RET L629P
|
Head and Neck Cancer
|
vorinostat + ABT-737 Sensitive: D – Preclinical
|
vorinostat + ABT-737 Sensitive: D – Preclinical
|